Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data

Bladder cancer is a very common malignancy. Although new treatment strategies have been developed, the identification of new therapeutic targets and reliable diagnostic/prognostic biomarkers for bladder cancer remains a priority. Generally, they are found among differentially expressed genes between patients and healthy subjects or among patients with different tumor stages. However, the classical approach includes processing these data taking into consideration only the expression of each single gene regardless of the expression of other genes. These complex gene interaction networks can be revealed by a recently developed systems biology approach called Weighted Gene Co-expression Network Analysis (WGCNA). It takes into account the expression of all genes assessed in an experiment in order to reveal the clusters of co-expressed genes (modules) that, very probably, are also co-regulated. If some genes are co-expressed in controls but not in pathological samples, it can be hypothesized that a regulatory mechanism was altered and that it could be the cause or the effect of the disease. Therefore, genes within these modules could play a role in cancer and thus be considered as potential therapeutic targets or diagnostic/prognostic biomarkers. Here, we have reviewed all the studies where WGCNA has been applied to gene expression data from bladder cancer patients. We have shown the importance of this new approach in identifying candidate biomarkers and therapeutic targets. They include both genes and miRNAs and some of them have already been identified in the literature to have a role in bladder cancer initiation, progression, metastasis, and patient survival.

[1]  A. Lopez‐Beltran,et al.  Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer , 2018, Front. Oncol..

[2]  Zhe Zhang,et al.  High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder , 2014, Tumor Biology.

[3]  Xiuheng Liu,et al.  MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  Lei Chen,et al.  WGCNA Application to Proteomic and Metabolomic Data Analysis. , 2017, Methods in enzymology.

[5]  T. Girke,et al.  Global isoform-specific transcript alterations and deregulated networks in clear cell renal cell carcinoma , 2018, Oncotarget.

[6]  Kaiyu Qian,et al.  Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis , 2017, Oncotarget.

[7]  Francesco Piva,et al.  SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans , 2009, Bioinform..

[8]  Qi Li,et al.  miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. , 2017, Oncology letters.

[9]  Per-Uno Malmström,et al.  Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. , 2013, The American journal of pathology.

[10]  H. Inoue,et al.  Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. , 2011, International journal of oncology.

[11]  F. Piva,et al.  Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis , 2017, Cellular Oncology.

[12]  F. Piva,et al.  SpliceAid 2: A database of human splicing factors expression data and RNA target motifs , 2012, Human mutation.

[13]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[14]  G. Pesole,et al.  A guideline for the annotation of UTR regulatory elements in the UTRsite collection. , 2015, Methods in molecular biology.

[15]  M. Galsky Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade , 2018, Nature Reviews Urology.

[16]  F. Piva,et al.  Cross-link immunoprecipitation data to detect polymorphisms lying in splicing regulatory motifs: a method to refine single nucleotide polymorphism selection in association studies. , 2012, Psychiatric genetics.

[17]  Scott B. Dewell,et al.  Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP , 2010, Cell.

[18]  Chien-Feng Li,et al.  Matrix metalloproteinase‐11 as a marker of metastasis and predictor of poor survival in urothelial carcinomas , 2016, Journal of surgical oncology.

[19]  Xuefeng Liu,et al.  Downregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder , 2016, Cancer medicine.

[20]  N. Seki,et al.  MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. , 2013, Urologic oncology.

[21]  Wu Wei,et al.  Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis , 2014, Molecular Genetics and Genomics.

[22]  Francesco Piva,et al.  ExportAid: database of RNA elements regulating nuclear RNA export in mammals , 2015, Bioinform..

[23]  Zhe Zhang,et al.  High FOXM1 expression was associated with bladder carcinogenesis , 2013, Tumor Biology.

[24]  H. Ozen Bladder cancer. , 1998, Current opinion in oncology.

[25]  H. Gaballah Integration of Gene Coexpression Network, GO Enrichment Analysis for Identification Gene Expression Signature of Invasive Bladder Carcinoma , 2016 .

[26]  Yair Lotan,et al.  Bladder cancer , 2020, Nature Reviews Disease Primers.

[27]  A. Fuente,et al.  From ‘differential expression’ to ‘differential networking’ – identification of dysfunctional regulatory networks in diseases , 2010 .

[28]  N. Seki,et al.  miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer , 2010, British Journal of Cancer.

[29]  A. Leiblich Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer , 2017, Current Urology Reports.

[30]  A. Minervini,et al.  T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin. , 2016, Human pathology.

[31]  N. Seki,et al.  Tumour‐suppressive microRNA‐24‐1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer , 2014, FEBS letters.

[32]  Yongsheng Song,et al.  MicroRNA‐195‐5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression , 2012, FEBS letters.

[33]  De-Shuang Huang,et al.  Mining the bladder cancer-associated genes by an integrated strategy for the construction and analysis of differential co-expression networks , 2015, BMC Genomics.

[34]  F. Piva,et al.  Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development , 2016, Cellular Oncology.

[35]  Xiaoping Liu,et al.  Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer , 2017, Front. Physiol..

[36]  Changbao Xu,et al.  Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma , 2013, Tumor Biology.

[37]  J. Steitz,et al.  EBV and human microRNAs co‐target oncogenic and apoptotic viral and human genes during latency , 2012, The EMBO journal.

[38]  Qing Wen,et al.  The prognostic significance of DAPK1 in bladder cancer , 2017, PloS one.

[39]  Y. Ge,et al.  Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis , 2017, OncoTargets and therapy.

[40]  K. Yanagihara,et al.  MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer , 2014, Cancer science.

[41]  Luigi Cormio,et al.  Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. , 2010, Histology and histopathology.

[42]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[43]  Sebastian D. Mackowiak,et al.  Circular RNAs are a large class of animal RNAs with regulatory potency , 2013, Nature.

[44]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[45]  Song Wu,et al.  Single-cell analyses of transcriptional heterogeneity in squamous cell carcinoma of urinary bladder , 2016, Oncotarget.

[46]  Y. Lotan,et al.  Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. , 2009, The Journal of urology.

[47]  Fedor V. Karginov,et al.  Remodeling of Ago2-mRNA interactions upon cellular stress reflects miRNA complementarity and correlates with altered translation rates. , 2013, Genes & development.

[48]  Wun-Jae Kim,et al.  Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. , 2010, Urology.

[49]  Cheng-yong Lei,et al.  The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer. , 2016, Urologic oncology.

[50]  Chang-Peng Wu,et al.  Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma , 2018, BMC Cancer.

[51]  A. G. de la Fuente From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.

[52]  Jun Wu,et al.  A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer , 2016, PloS one.

[53]  Yaoting Gui,et al.  Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer , 2014, Tumor Biology.

[54]  Kefeng Wang,et al.  MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1 , 2014, Cancer Cell International.

[55]  Uwe Ohler,et al.  Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. , 2011, Cell host & microbe.

[56]  Beverly L. Davidson,et al.  Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP , 2016, Nucleic acids research.

[57]  N. Yoshioka,et al.  Periostin is down‐regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells , 2005, International journal of cancer.

[58]  M. J. van de Vijver,et al.  Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets , 2014, Genome Biology.

[59]  Xiangyi Zheng,et al.  Cyclin‐dependent kinase 4 is a novel target in micoRNA‐195‐mediated cell cycle arrest in bladder cancer cells , 2012, FEBS letters.

[60]  N. Seki,et al.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer , 2011, British Journal of Cancer.

[61]  M. Haleyurgirisetty,et al.  Identification of Host Micro RNAs That Differentiate HIV-1 and HIV-2 Infection Using Genome Expression Profiling Techniques , 2016, Viruses.

[62]  Mattia D'Antonio,et al.  SpliceAid-F: a database of human splicing factors and their RNA-binding sites , 2012, Nucleic Acids Res..

[63]  J. Rader,et al.  Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer , 2006, Oncogene.

[64]  Seyed Hassan Paylakhi,et al.  A microRNA signature associated with chondrogenic lineage commitment , 2012, Journal of Genetics.

[65]  A. Scorilas,et al.  Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. , 2015, Carcinogenesis.

[66]  Hailong Zhu,et al.  Network biomarkers reveal dysfunctional gene regulations during disease progression , 2013, The FEBS journal.

[67]  H. Hirata,et al.  Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression. , 2017, Oncology letters.

[68]  P. Pourquier,et al.  Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer , 2017, Cancer Chemotherapy and Pharmacology.

[69]  Teresa Colombo,et al.  TP53 regulates miRNA association with AGO2 to remodel the miRNA–mRNA interaction network , 2016, Genome research.

[70]  M. Zavolan,et al.  A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins , 2011, Nature Methods.

[71]  G. Sauter,et al.  TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. , 2004, The American journal of pathology.

[72]  A. Shang,et al.  MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[73]  N. Seki,et al.  Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. , 2012, International journal of oncology.

[74]  Hideyasu Matsuyama,et al.  Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. , 2007, Cancer genetics and cytogenetics.

[75]  F. Piva,et al.  LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer , 2018, Carcinogenesis.

[76]  C. Bellantuono,et al.  An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes , 2010, Human psychopharmacology.

[77]  Wun-Jae Kim,et al.  Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer , 2016, Investigative and clinical urology.

[78]  T. Kislinger,et al.  The emerging role of extracellular vesicles as biomarkers for urogenital cancers , 2014, Nature Reviews Urology.

[79]  X. Zu,et al.  microRNA-195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription-3 signaling. , 2015, Experimental and therapeutic medicine.

[80]  R. Montironi,et al.  Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma , 2015, Oncotarget.

[81]  C. Bellantuono,et al.  Bioinformatic analyses to select phenotype affecting polymorphisms in HTR2C gene , 2011, Human psychopharmacology.

[82]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[83]  Wei Zhang,et al.  Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. , 2006, Oncology reports.

[84]  Yukio Homma,et al.  UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy. , 2013, International journal of clinical and experimental pathology.

[85]  C. Sander,et al.  Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. , 2011, Genes & development.

[86]  M. Climent,et al.  SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. , 2016, Pharmacogenomics.

[87]  B. Cullen,et al.  In-Depth Analysis of the Interaction of HIV-1 with Cellular microRNA Biogenesis and Effector Mechanisms , 2013, mBio.

[88]  S. Horvath,et al.  Functional organization of the transcriptome in human brain , 2008, Nature Neuroscience.